Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.7K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.7K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.9K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.2K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

888
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
888

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer.

Histopathology·2026
Same author

Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration.

European journal of ophthalmology·2026
Same author

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.

Clinical lung cancer·2025
Same author

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Nature communications·2025
Same author

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.

Future oncology (London, England)·2025

Related Experiment Video

Updated: Feb 20, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.6K

Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach.

Olivier Le Rouzic1, Nicolas Roche2, Alexis B Cortot1

  • 1Department of Respiratory Diseases, University of Lille, CHU Lille, Lille.

Chest
|October 22, 2017
PubMed
Summary
This summary is machine-generated.

This study statistically confirms the frequent exacerbator phenotype in Chronic Obstructive Pulmonary Disease (COPD). The established threshold of two exacerbations per year accurately identifies patients with greater disease severity and poorer quality of life.

Keywords:
COPDcohort studiesexacerbation

More Related Videos

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.5K
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.7K

Related Experiment Videos

Last Updated: Feb 20, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.6K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.5K
Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice
10:37

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

13.7K

Area of Science:

  • Pulmonary Medicine
  • Clinical Epidemiology

Background:

  • The
  • frequent exacerbator
  • phenotype in Chronic Obstructive Pulmonary Disease (COPD) is typically defined as at least two exacerbations annually, significantly impacting patient health.
  • However, statistical validation of this phenotype and its defining thresholds using unbiased methods is needed.

Purpose of the Study:

  • To confirm the existence of the frequent exacerbator phenotype in COPD patients.
  • To validate the clinical relevance of the established threshold for identifying frequent exacerbators.

Main Methods:

  • Analysis of prospectively recorded exacerbations from the French EXACO cohort.
  • Utilized KmL clustering for longitudinal data and ROC curve analysis to determine optimal thresholds.
  • Performed univariate and multivariate analyses to characterize patient clusters.

Main Results:

  • Identified two distinct patient clusters based on exacerbation frequency: one with 2.89 exacerbations/year and another with 0.71 exacerbations/year.
  • Confirmed that two moderate to severe exacerbations per year is the optimal threshold to distinguish these clusters.
  • Frequent exacerbators exhibited greater airflow limitation, more symptoms, and impaired health-related quality of life.

Conclusions:

  • The study validates the existence and clinical significance of the frequent exacerbator subgroup in COPD.
  • The current threshold of two exacerbations per year is confirmed as a relevant clinical marker for this phenotype.